Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial

There is still no clinical evidence available to support or to oppose corticosteroid treatment for coronavirus disease 2019 (COVID-19) pneumonia. This study was a prospective, multicenter, single-blind, randomized control trial.

The Limited Sensitivity of Chest Computed Tomography Relative to Reverse Transcription Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus-2 Infection: A Systematic Review on COVID-19 Diagnostics

Several studies suggest the sensitivity of chest computed tomography (CT) is far greater than that of reverse transcription-polymerase chain reaction (RT-PCR) This systematic review aims to determine the true sensitivity of CT for severe acute respiratory syndrome coronavirus-2 infection according to the unbiased (low risk) studies.

Persistent viral shedding of SARS-CoV-2 in faeces - a rapid review

53.9% of those tested for fecal were positive for the virus. duration of viral shedding ranged from 1 to 33 days after a negative nasopharyngeal swab with one result remaining positive 47 days after onset of symptoms. There is insufficient evidence to suggest that CO VID-19 is transmitted via faecally shed virus.

A Review on Mode of Delivery during COVID-19 between December 2019 and April 2020

The study aims to determine the mode of delivery in pregnant women with coronavirus disease 2019 (COVID-19) 68.9% of women delivered via cesarean section during the SARS-CoV-2 pandemic. Despite eight of 206 newborns testing positive for SARS, there remains no definitive evidence of vertical transmission.

Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis

There is limited literature on the prevalence of pre-existing cerebrovascular diseases (CeVD) Patients with CeVD had 2.67-fold (1.75-4.06) in COVID-19 patients. Patients with CeVD had 2.67-fold (1.75-4.06) higher odds of poor outcomes. Extra precautions should be taken in managing such patients during the ongoing pandemic

Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis

Crowded indoor environments are high-risk settings for the transmission of SARS-CoV-2. Estimated household secondary attack rate was 16.6% (95% CI, 14.0%-19.3%)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, is safe and well-tolerated. We did a randomized, double-blind, placebo-controlled, phase 1/2 trial at Shangqiu City Liangyuan District Center for Disease Control and Prevention in Henan Province, China.

Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study)

The study aimed at evaluating safety and efficacy of ozone therapy (OT) No adverse events were reported in the OZ group, as against 2 deaths reported in the ST group.

Departments

Recent Posts